Monoclonal antibody · Antagonist of Siglec-15 · developed by NextCure
NC318 is a humanized IgG1 monoclonal antibody that binds Siglec-15 on tumor-associated macrophages and certain tumor cells. It is being studied in solid tumors, including non-small cell lung cancer, breast cancer, head and neck squamous cell carcinoma, endometrial cancer, melanoma, colorectal cancer, urothelial carcinoma and cholangiocarcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04699123 | Phase 2 | Advanced Non-small Cell Lung Cancer | Active not recruiting | NXTC |
| NCT03665285 | Phase 1/2 | Advanced or Metastatic Solid Tumors | Completed | NXTC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Non-small Cell Lung CancerAdvanced or Metastatic Solid TumorsBreast CancerCholangiocarcinomaCRCEndometrial CancerHead and Neck Squamous Cell CarcinomaLung CancerMelanomaUrothelial Carcinoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.
See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NXTC catalysts and pipeline →